8.38
8.38 (0%)
As of Feb 14, 2025
Kala Pharmaceuticals, Inc. [KALA]
Source:
Company Overview
Kala Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the front and back of the eye.
| Country | United States |
| Headquarters | arlington, massachusetts |
| Phone Number | 781-996-5252 |
| Industry | manufacturing |
| CEO | Mark Iwicki |
| Website | www.kalarx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-41 |
| Net Income | $-38.5 |
| Net Cash | $0.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -69.1% |
| Profit as % of Stockholder Equity | -312.3% |
Management Effectiveness
| Return on Equity | -312.3% |
| Return on Assets | -69.4% |
| Turnover Ratio | |
| EBITA | $-41 |
Balance Sheet and Cash Flow Measures
| Total Assets | $55.5 |
| Total Liabilities | $43.2 |
| Operating Cash Flow | $-29.4 |
| Investing Cash Flow | $-0.2 |
| Financing Cash Flow | $29.9 |
